Overview

This article presents a protocol for measuring KDM1A target engagement in human or animal samples treated with KDM1A inhibitors. The method utilizes chemoprobe tagging and immunoassays for direct quantification of target occupation.

Key Study Components

Area of Science

Neuroscience
Pharmacology
Drug Development

Background

Target engagement is crucial for understanding drug efficacy.
This technique allows direct measurement of KDM1A interactions.
Applicable in both basic research and clinical trials.
Focuses on oncological CNS diseases treated with KDM1A inhibitors.

Purpose of Study

To assess the interaction of KDM1A inhibitors with their target.
To measure dose effects and dynamics of KDM1A engagement.
To provide a protocol for preclinical and clinical studies.

Methods Used

Chemoprobe tagging of KDM1A enzyme.
Direct quantification using chemoprobe-based immunoassays.
Application of the method to various KDM1A inhibitors.
Demonstration of the procedure by a lab operation manager.

Main Results

Successful measurement of KDM1A target engagement.
Demonstrated binding of ORY-1001 to KDM1A in cell treatments.
Potential for use in pharmacodynamics studies.
Protocol adaptable for other KDM1A inhibitors.

Conclusions

This technique enhances the understanding of drug-target interactions.
It provides a reliable method for assessing pharmacodynamics.
Can be utilized in various research and clinical contexts.

Frequently Asked Questions

What is KDM1A?

KDM1A is a histone demethylase involved in gene regulation.

How does the chemoprobe work?

The chemoprobe tags the KDM1A enzyme, allowing for quantification of its engagement with inhibitors.

Can this method be used for other targets?

Yes, the strategy can be adapted for other protein targets beyond KDM1A.

What diseases can this technique be applied to?

It is applicable in oncological CNS diseases and potentially others treated with KDM1A inhibitors.

Who demonstrated the procedure?

The procedure was demonstrated by Raquel Ruiz, an operation manager in the PK/PD discovery platform.

What are the advantages of this technique?

It allows for direct measurement of drug-target interactions, providing insights into pharmacodynamics.

Institution - Oryzon Genomics

Articles Published in JoVE